VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
APYX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
APYXApyx Medical Corporation
$4.50$188M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksAPYXFinancials

Apyx Medical Corporation (APYX) Financials

30Y historyFree accessUpdated daily

Revenue growth remains highly volatile, fluctuating between a 15.6% decline in 2024Q1 and a 34.7% surge in 2025Q4, while structural gross margin instability persists with a 2026Q1 margin of 37.4%.

APYX Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue55.9M52.84M48.1M52.35M44.51M48.52M27.71M28.23M16.69M38.88M36.63M29.52M27.68M23.66M27.67M25.41M24.23M26.95M28.1M28.78M26.68M20.21M20.5M16.55M12.45M11.48M9.94M9.6M8.44M7.37M7.49M
Revenue Growth %18.22%9.86%-8.11%17.61%-8.26%75.08%-1.86%69.21%-57.09%6.16%24.08%6.64%16.99%-14.5%8.89%4.87%-10.1%-4.07%-2.37%7.88%31.99%-1.39%23.83%32.97%8.38%15.58%3.53%13.69%14.52%-1.53%35.59%
Cost of Goods Sold37.86M33.81M18.74M18.59M15.38M14.92M10.21M9.14M5.89M19.12M18.71M16.96M18.69M14.46M16.34M14.68M14.24M15.1M16.25M17.46M16.08M12.65M12.51M9.43M7.19M5.72M4.6M4.59M5.27M4.14M4.13M
COGS % of Revenue-63.98%38.96%35.51%34.55%30.74%36.83%32.37%35.32%49.18%51.09%57.46%67.52%61.12%59.04%57.77%58.78%56.02%57.83%60.68%60.26%62.59%61.06%57%57.77%49.85%46.26%47.81%62.48%56.15%55.23%
Gross Profit18.04M19.03M29.36M33.76M29.13M33.6M17.5M19.09M10.79M19.76M17.91M12.56M8.99M9.2M11.33M10.73M9.99M11.85M11.85M11.32M10.6M7.56M7.98M7.12M5.26M5.76M5.34M5.01M3.17M3.23M3.35M
Gross Margin %32.27%36.02%61.04%64.49%65.45%69.26%63.17%67.63%64.68%50.82%48.91%42.54%32.48%38.88%40.96%42.23%41.22%43.98%42.17%39.32%39.74%37.41%38.94%43%42.23%50.15%53.74%52.19%37.52%43.85%44.77%
Gross Profit Growth %--35.17%-13.03%15.89%-13.3%91.96%-8.33%76.91%-45.38%10.3%42.67%39.65%-2.24%-18.84%5.61%7.44%-15.75%0.05%4.71%6.74%40.19%-5.25%12.15%35.39%-8.74%7.86%6.61%58.12%-2%-3.55%45.36%
Operating Expenses22.35M25.48M48.2M51.02M52.69M48.05M37.59M39.96M23.65M23.5M21.71M19.54M14.84M11.22M10.29M11.5M11.45M11.14M10.56M9.21M7.98M7.16M6.7M6.4M5.73M5.18M4.81M7.16M4.09M2.89M2.87M
OpEx % of Revenue-48.22%100.21%97.46%118.38%99.04%135.64%141.54%141.75%60.44%59.27%66.2%53.61%47.44%37.18%45.25%47.27%41.33%37.58%32%29.9%35.42%32.7%38.69%46.04%45.07%48.41%74.57%48.43%39.25%38.35%
Selling, General & Admin31.78M36.12M43.13M48.87M48.15M43.73M33.67M36.23M21.18M21.05M19.09M17.38M13.43M9.96M8.96M10.3M9.6M9.06M8.5M7.57M6.79M6.01M5.76M5.6M4.91M4.71M3.9M6.46M1.75M01.34M
SG&A % of Revenue-68.35%89.65%93.35%108.18%90.13%121.49%128.32%126.95%54.13%52.12%58.89%48.5%42.11%32.37%40.54%39.62%33.6%30.24%26.29%25.45%29.74%28.08%33.86%39.46%41.04%39.25%67.27%20.76%-17.87%
Research & Development3.33M3.37M5.08M4.84M4.54M4.32M3.92M3.73M2.47M2.46M2.62M2.16M1.42M1.26M1.33M1.2M1.85M2.08M2.06M1.64M1.19M985.81K907.39K717.35K693.71K463.13K513.02K379.83K183.17K96.74K105.7K
R&D % of Revenue-6.38%10.56%9.25%10.21%8.91%14.15%13.21%14.8%6.31%7.15%7.32%5.12%5.33%4.8%4.71%7.65%7.73%7.33%5.71%4.45%4.88%4.43%4.33%5.57%4.03%5.16%3.96%2.17%1.31%1.41%
Other Operating Expenses0-14.01M0-2.69M0000-203K0000020K000000161.19K39.29K81.91K124.44K0396.81K321.17K2.15M2.8M1.43M
Operating Income-4.31M-6.45M-18.84M-17.26M-23.56M-14.45M-20.08M-20.87M-13.6M-5.26M-3.79M-6.99M-5.85M-3.67M1.05M-18K-2.75M714.85K1.29M2.11M2.62M403.97K1.28M712.4K-473.89K583.58K529.9K-2.15M-920.16K339.58K480.4K
Operating Margin %-7.7%-12.2%-39.18%-32.97%-52.94%-29.78%-72.47%-73.91%-81.51%-13.54%-10.35%-23.67%-21.13%-15.49%3.78%-0.07%-11.36%2.65%4.6%7.32%9.84%2%6.24%4.3%-3.81%5.08%5.33%-22.38%-10.9%4.61%6.42%
Operating Income Growth %-65.79%-9.19%26.75%-63.08%28.06%3.77%-53.45%-158.31%-38.84%45.72%-19.44%-59.55%-450.48%5911.11%99.35%-484.98%-44.64%-38.7%-19.72%549.52%-68.4%79.47%250.33%-181.2%10.13%124.67%-133.44%-370.97%-29.31%318.86%
EBITDA-3.62M-5.79M-18.25M-16.57M-22.67M-13.54M-19.2M-20.11M-12.93M-4.57M-3.06M-6.17M-4.97M-2.84M1.9M907K-1.75M1.76M2.26M2.88M3.15M949.84K1.67M1.03M-199.02K1.11M926.71K-1.83M-133.07K650.72K741K
EBITDA Margin %-6.47%-10.96%-37.93%-31.65%-50.94%-27.92%-69.27%-71.24%-77.5%-11.75%-8.35%-20.91%-17.97%-12%6.88%3.57%-7.21%6.55%8.06%10%11.82%4.7%8.17%6.21%-1.6%9.65%9.33%-19.03%-1.58%8.83%9.9%
EBITDA Growth %75.38%68.26%-10.13%26.93%-67.38%29.44%4.57%-55.56%-183.02%-49.41%50.47%-24.15%-75.17%-249.19%109.81%151.95%-198.95%-22.08%-21.3%-8.75%231.96%-43.25%62.95%616.07%-117.96%19.54%150.73%-1272.81%-120.45%-12.18%1627.84%
D&A (Non-Cash Add-back)687K655K599K692K890K903K887K754K669K696K734K812K876K827K857K925K1.01M1.05M973.07K770.83K529.26K545.88K395.12K314.68K274.88K524.24K396.81K321.17K787.09K311.14K260.6K
EBIT-3.66M-6.45M-17.4M-18.8M-22.9M-14.81M-19.36M-19.83M-14.59M-13.7M-3.73M-5.19M-13.13M-5.71M1.07M269K-2.24M739.21K2.84M2.11M2.62M403.97K1.27M663.46K-473.89K632.06K529.9K626.03K-920.16K339.58K480.4K
Net Interest Income-4.53M-4.48M-4.3M-1.56M142K1K195K1.38M512K-136K-158K-158K-151K-1.44M-232K-237K-223K-52K-9.7K140.25K86.93K24.26K-11.83K-31.08K-43.24K-60.58K-38.06K0-99.68K0-75.8K
Interest Income1.05M1.11M1.61M921K157K11K241K1.39M616K00007K012K024.36K48.76K142.72K103.09K46.96K3.26K2.98K5.21K10.11K28.75K04.16K00
Interest Expense5.58M5.59M5.91M2.48M15K10K46K8K104K136K158K158K151K237K232K249K223K76.37K58.46K2.47K16.16K22.7K15.09K34.06K48.45K70.69K66.8K0103.84K075.8K
Other Income/Expense-4.41M-4.39M-4.46M-4.02M651K-372K674K1.03M-1.09M-8.57M-94K1.64M-7.44M-2.29M-212K50K290K-52.01K1.49M140.25K86.93K24.26K-11.83K-31.08K-40.87K-431.47K8.79K3.25K-77.88K-240.39K-64.8K
Pretax Income-8.71M-10.84M-23.31M-21.28M-22.91M-14.82M-19.41M-19.84M-13.27M-5.22M-3.89M-5.34M-13.29M-5.95M834K32K-2.46M662.84K2.78M2.25M2.71M428.22K1.27M681.32K-514.76K200.59K538.68K-2.14M-998.05K99.19K415.6K
Pretax Margin %-15.58%-20.5%-48.45%-40.65%-51.47%-30.55%-70.04%-70.25%-79.53%-13.42%-10.61%-18.11%-47.99%-25.16%3.01%0.13%-10.16%2.46%9.88%7.81%10.16%2.12%6.18%4.12%-4.14%1.75%5.42%-22.35%-11.82%1.35%5.55%
Income Tax364K270K252K-2.43M367K380K-7.5M-130K-3.78M-156K64K25K4M-1.61M217K-77K-927K67.32K945.42K-148.84K47.57K32.02K-272.72K31.08K0-211.19K29.27K35.81K000
Effective Tax Rate %-4.18%-2.49%-1.08%11.43%-1.6%-2.56%38.66%0.66%28.46%2.99%-1.65%-0.47%-30.09%27.1%26.02%-240.63%37.65%10.16%34.04%-6.62%1.75%7.48%-21.53%4.56%0%-105.29%5.43%-1.67%0%0%0%
Net Income-9.17M-11.21M-23.46M-18.71M-23.18M-15.17M-11.9M-19.71M64.01M-5.06M-3.95M-5.37M-17.28M-4.34M617K109K-1.53M595.52K1.83M2.4M2.68M406.21K1.51M681.32K-514.76K784.29K500.63K-2.18M-998.05K99.19K407.3K
Net Margin %-16.4%-21.22%-48.78%-35.75%-52.09%-31.27%-42.93%-69.79%383.61%-13.02%-10.78%-18.19%-62.43%-18.34%2.23%0.43%-6.34%2.21%6.52%8.34%10.06%2.01%7.38%4.12%-4.14%6.83%5.04%-22.75%-11.82%1.35%5.44%
Net Income Growth %54.24%52.22%-25.38%19.28%-52.81%-27.54%39.63%-130.79%1364.5%-28.15%26.44%68.93%-298.29%-803.24%466.05%107.1%-357.76%-67.49%-23.69%-10.53%560.55%-73.13%121.92%232.35%-165.63%56.66%122.92%-118.81%-1106.19%-75.65%364.31%
Net Income (Continuing)-9.08M-11.11M-23.56M-18.85M-23.28M-15.2M-11.91M-19.71M-10.78M-13.68M-11.55M-5.37M-17.28M-4.34M617K109K-1.53M595.52K1.83M2.25M2.68M406.21K1.51M632.38K-514.76K784.29K500.63K-2.18M-998.05K99.19K415.6K
Discontinued Operations0000000000000000000000000000000
Minority Interest256K291K125K221K211K305K138K0000000000000120K140K000000000
EPS (Diluted)-0.22-0.27-0.66-0.54-0.67-0.44-0.35-0.581.86-0.16-0.14-0.19-0.97-0.250.030.01-0.090.030.110.130.160.030.090.05-0.040.060.04-0.16-0.070.010.05
EPS Growth %60.95%59.09%-22.22%19.4%-52.27%-25.71%39.66%-131.18%1262.5%-14.29%26.32%80.41%-288%-933.33%200%111.31%-394.67%-72.73%-15.38%-18.75%433.33%-66.67%80%240.06%-159.5%50%125%-122.53%-699.17%-76%348.76%
EPS (Basic)--0.27-0.66-0.54-0.67-0.44-0.35-0.581.93-0.16-0.14-0.22-0.98-0.250.040.01-0.090.040.110.150.190.030.110.05-0.040.060.04-0.16-0.070.010.05
Diluted Shares Outstanding42.16M42.16M35.54M34.62M34.52M34.33M34.21M34.07M34.37M31.43M27.45M27.75M17.76M17.67M17.79M17.67M17.37M17.84M17.09M17.68M16.91M15.75M16.8M13.63M14.41M14.76M16.07M13.88M13.88M8.44M7.66M
Basic Shares Outstanding42.16M42.16M35.54M34.62M34.52M34.33M34.21M34.07M33.19M31.42M27.43M24.33M17.68M17.48M17.63M17.6M17.37M16.9M16.07M15.32M14.54M13.92M13.75M13.63M13.2M13.45M13.9M13.88M13.88M8.19M7.66M
Dividend Payout Ratio-------------------------------

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetStrained
Cash FlowBurning
Top Statement Risk

Persistent operating margin deficits

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Volatile Revenue Growth Patterns Observed

As reported in recent financial statements, Apyx Medical's revenue growth has exhibited significant quarterly volatility, fluctuating between a 15.6% decline in 2024Q1 and a 34.7% surge in 2025Q4, suggesting that the company's top-line trajectory remains highly sensitive to seasonal demand and potential lumpiness in capital equipment sales.

The inconsistent revenue performance indicates that the company has yet to establish a predictable recurring revenue base sufficient to smooth out the cyclical nature of its aesthetic device business. Investors should monitor whether the recent growth spikes represent sustainable adoption of the Renuvion platform or merely timing-related fluctuations in distributor sell-in.

Structural Gross Margin Instability Persists

Based on the provided income statement data, gross margins have oscillated wildly from a low of -10.5% in 2025Q4 to a peak of 64.4% in 2025Q3, reflecting significant underlying challenges in manufacturing efficiency and the potential impact of inventory write-downs or unfavorable product mix shifts.

Such extreme variance in gross profitability suggests that the company's cost of goods sold is not yet optimized for scale, potentially due to high overhead absorption requirements or intermittent supply chain cost pressures. This lack of margin stability complicates the valuation of the business, as it obscures the true unit economics of the core Advanced Energy segment.

Operating Leverage Remains Elusive Currently

According to historical income statement filings, Apyx Medical has struggled to achieve positive operating leverage, as SG&A expenses frequently exceed gross profit, resulting in persistent operating losses that suggest the company's commercial infrastructure is currently too costly relative to the revenue generated by its current installed base.

The inability to scale operating income alongside revenue growth implies that the company's investment in its direct sales force and clinical trials has not yet reached an inflection point of efficiency. Without a meaningful reduction in the ratio of SG&A to revenue, the path to sustained profitability appears increasingly dependent on aggressive top-line expansion.

Sustainability of Current Business Model

Analysis of the company's financial history reveals that despite periodic revenue growth, the persistent negative net margins and recurring reliance on capital markets for liquidity raise significant questions regarding the long-term viability of the current business model without a fundamental shift in cost structure or pricing power.

Short-sellers would likely focus on the company's inability to generate consistent positive cash flow, viewing the high SG&A spend as a structural impediment rather than a temporary investment. The risk remains that the company may be forced to dilute shareholders further if it cannot demonstrate a clear, near-term path to operational self-sufficiency.

APYX — Frequently Asked Questions

Quick answers to the most common questions about buying APYX stock.

What was Apyx Medical Corporation's (APYX) revenue in 2025?

For fiscal year 2025, Apyx Medical Corporation (APYX) reported total revenue of $52.8M. This represents a 605.9% increase compared to $7.5M in 1996.

Is Apyx Medical Corporation (APYX) profitable?

Apyx Medical Corporation (APYX) reported a net loss of $11.2M for the fiscal year ending 2025.

What is Apyx Medical Corporation's operating profit margin?

Apyx Medical Corporation (APYX) reported an operating income of $-6.4M, resulting in an operating profit margin of -12.2%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Apyx Medical Corporation's gross profit and gross margin?

Apyx Medical Corporation (APYX) generated $19.0M in gross profit for the year, representing a gross profit margin of 36.0%. This demonstrates the company's core pricing power and production efficiency.